Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Vor Biopharma reports promising data from Phase 1/2 VBP101 study. 100% engraftment achieved with trem-cel and Mylotarg in patients. Vor plans to discuss pivotal trial design with FDA soon. Cash reserves of $85.9 million, funding operations into 2025. VOR stock up 28.5% following positive trial results.
- Vor Biopharma reports promising data from Phase 1/2 VBP101 study.
- 100% engraftment achieved with trem-cel and Mylotarg in patients.
- Vor plans to discuss pivotal trial design with FDA soon.
- Cash reserves of $85.9 million, funding operations into 2025.
- VOR stock up 28.5% following positive trial results.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.